Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Relief Therapeutics Holding AG

http://www.relieftherapeutics.com/

Latest From Relief Therapeutics Holding AG

Coronavirus Notebook: EU Invests In Convalescent Plasma, ACT-Accelerator Wants More Vaccines

InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.

Europe Switzerland

Stockwatch: Orphans are better, if they work

InterMune’s therapeutic area for many years has been lung diseases and more specifically idiopathic pulmonary fibrosis (IPF). The company's treatment for IPF, pirfenidone, is the only approved drug, and yet it is not available everywhere. The US FDA, for instance, issued a complete response letter in May. Furthermore, InterMune's original intention of partnering its drug has not been realised. What lies behind such regulatory and commercial reticence?

Cardiovascular Orthopedics

Deals Shaping the Medical Industry (04/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Actelion hit by negative Tracleer data

Actelion's Tracleer (bosentan) failed to reduce morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF), show top-line Phase III trial results of the BUILD-3 trial. The Swiss company says that it will not carry out any future trials with the endothelin receptor antagonist in IPF.

Cardiovascular Orthopedics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • THERAMetrics Holding AG
UsernamePublicRestriction

Register